ReViral is a UK-based biotechnology company with a portfolio of drugs to treat Respiratory Syncytial Virus (RSV) infection. RSV currently represents a major unmet medical need in children, the elderly and the immunocompromised.
Our most advanced programme, RV521, is a highly potent, orally-administered inhibitor of RSV fusion protein, and has demonstrated top-line safety and pharmacokinetic data in Phase 1 single and multiple ascending dose (SAD and MAD) trials. RV521 has successfully completed a Phase 2a proof-of-concept study in adult volunteers. RV521 will start clinical trials in patients in 2018.